Esophageal cancer (EC) is an aggressive malignancy with an increasing incidence and a
poor prognosis. EC is histologically divided into two major categories: adenocarcinoma …

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide.
Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and …

Introduction Major pathologic regression after neoadjuvant therapy is a strong and favorable
prognostic factor in several types of cancer (breast, rectal and bladder). This information is …

Esophageal cancer is the sixth most common cause of cancer deaths worldwide.
Adenocarcinoma is more common in North America and Western European countries …

Upper gastrointestinal tract cancers originating in the esophagus, esophagogastric junction
(EGJ), and stomach constitute a major health problem around the world. An estimated …

Objective: To determine whether adjuvant chemotherapy (AC) after neoadjuvant
chemoradiation and esophagectomy is associated with improved overall survival for patients …

Objective The preferred neoadjuvant treatment for gastroesophageal junction (GEJ)
adenocarcinoma is still matter of debate. We conducted a meta-analysis to assess the …

Background The benefit of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy
for treating cancer of the esophagus or the gastroesophageal junction remains controversial …

Objectives: To identify the effective approach between neoadjuvant chemotherapy (NCT)
and chemoradiotherapy (NCRT) by comparing patient survival and complications. Methods …

BACKGROUND: Neoadjuvant chemoradiation (CRT) is an accepted treatment for locally
advanced esophageal carcinoma. A survival benefit has not been definitively established …